Cooper/Haims Advisors
PMVP icon

Cooper/Haims Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Cooper/Haims Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-39,021
Closed -$52.3K – 123
2026
Q2 		$52.3K Buy
+39,021
New +$50.1K 0.02% 114

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
BIT Capital
BIT Capital Berlin, Germany $2.89B AUM 111.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aldebaran Capital
Aldebaran Capital Carmel, Indiana $139M AUM 35.88% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Cooper/Haims Advisors's PMVP Position: Q3 2026 in Review

Cooper/Haims Advisors sold out of PMV Pharmaceuticals (PMVP) in Q3 2026, closing a stake of 39,021 shares — an estimated $52.3K sold.

Cooper/Haims Advisors first reported a position in PMVP in Q2 2026 and held it in 1 quarter. The position peaked at $52.3K in Q2 2026. 36 funds tracked by Wall St. Rank hold PMVP as of Q3 2026.

  • Cooper/Haims Advisors reported no remaining PMV Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Cooper/Haims Advisors sold 39,021 PMV Pharmaceuticals shares in Q3 2026, an estimated $52.3K.
  • Cooper/Haims Advisors first reported a position in PMV Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Cooper/Haims Advisors's PMV Pharmaceuticals position peaked at $52.3K in Q2 2026.
  • 36 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2026.

Based on Cooper/Haims Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.